New FDA approvals in July include therapies for NSCLC, relapsed multiple myeloma, liver cancer, and B-cell malignancies.

This is an actor portrayal of a hypothetical patient profile developed for educational purposes based on characteristics of patients with multiple myeloma as seen in clinical practice. The ...

Panelists discuss the complexities of managing metastatic melanoma with asymptomatic brain metastases in patients with good performance status, emphasizing challenges posed by treatment resistance and ...

Panelists discuss the importance of effective communication and multidisciplinary collaboration in managing immunotherapy toxicities and ensuring seamless patient care, while highlighting promising ...